FOR IMMEDIATE RELEASE

U.S. MARKET FOR ORGAN AND TISSUE TRANSPLANTATION WORTH $28.2 BILLION IN 2013

Wellesley, Mass—According to a new technical market research report, TRENDS IN ORGAN AND TISSUE TRANSPLANTATION AND ALTERNATIVE TECHNIQUES (HLC012D) from BCC Research (www.bccresearch.com), the U.S. market for organ and tissue transplantation generated $18.9 billion in 2007. This is expected to increase to $20.9 billion in 2008 and $28.2 billion in 2013, for a compound annual growth rate (CAGR) of 6.1%. 

The market is broken down into solid organ and tissue transplantation. Of these, the solid organ transplantation segment has the larger share of the market. Worth $9.6 billion in 2007, this segment should increase to $10.5 billion in 2008 and $13.8 billion in 2013, for a CAGR of 5.7%.

The tissue transplantation segment is experiencing faster growth and is expected to eclipse organ transplantation by 2013. The tissue transplantation segment generated $9.2 billion in 2007 and an estimated $10.4 billion in 2008. This should increase at a CAGR of 6.5% to reach $14.3 billion in 2013. Growth in this sector is driven by skin/skin replacement products and procedures, as well as by bone grafting procedures.

The primary factor driving the future of transplantation is the shortage of organs. Increasing competition for limited supplies of organs will drive better procurement and preservation techniques. Additionally, there are efforts underway to enhance the supply of organs. Several trends in place include donor registration drives, increased organ recovery rates, reduced waste of potential organs, and better organ preservation techniques. The rapid spread of organ transplant services also will increase the competition for both organs and patients.

At the same time, the shortage of transplantable organs has created a window of opportunity for alternatives to transplantation. In the case of hearts and livers, those alternatives are beginning to be commercially available, and the expanding use of alternatives to pancreas or human islet cell transplants soon may be available as well.

Growth in the immunosuppressant and post-transplant monitoring segments are expected to continue to provide substantial impetus to the market as transplantation successes and survival rates climb.

Organ and Tissue Transplantation and Alternatives ( HLC012D )
Target Date: October 2008    Price: $4850.00

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, Telephone: 866-285-7215; Email: editor@bccresearch.com as the source and publisher, along with report number, which can be found in the first paragraph of this release. Thank you.